ArticleTranslational cancer research2026
A risk score model based on glycosylation-related genes for predicting radioresistance and prognosis of lung adenocarcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiotherapy resistance (RR) is the main cause of radiotherapy failure in lung cancer patients, and its mechanisms are still unrevealed. Glycosylation, as a type of post-translational modification of proteins, plays a key role in tumor progression. Some studies have shown a strong link between glycosylation and RR. However, the absence of a systematic glycosylation-related genes (GRGs) model to predict radiotherapy efficacy in lung adenocarcinoma (LUAD) patients highlights a significant clinical and research gap. The aim of the research was to investigate the prognostic characteristics of GRGs in LUAD treated with radiotherapy. Methods: RNA sequencing data of LUAD were obtained from The Cancer Genome Atlas (TCGA) database. The expression and prognostic significance of GRGs in patients who underwent radiotherapy were analyzed with bioinformatics tools, and the Gene Expression Omnibus (GEO) database was used for verification. Gene set enrichment analysis (GSEA), Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), etc. were used to analyze the potential mechanism of risk model constructed by GRGs in LUAD. The predictive significance of risk model was investigated by immune infiltration analysis, somatic mutations, and drug susceptibility analysis, etc. Single-cell sequencing and molecular docking were used to find new potential targets for LUAD patients. Finally, our bioinformatics analysis results were verified by wet experiments. Results: GO and KEGG analyses found that glycosylation played a pivotal role in LUAD RR. Forty-four differentially expressed radiotherapy-related glycosylation genes (DERRGGs) were identified in LUAD. Conclusions: This study constructed glycosylation related RiskScore to predict the prognosis of LUAD patients, specifically in the context of radiotherapy. We explored the relationship between radiotherapy efficacy, glycosylation and prognosis of LUAD patients, which provides new ideas for personalized treatment of LUAD patients. And we suggested that tretinoin may be a potential radiotherapy sensitizer for LUAD, providing a foundation for future investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.